

Review

Not peer-reviewed version

Novel Antibacterial Approaches and Therapeutic Strategies

[Gustavo A Niño-Vega](#)^{*}, [Jorge A Ortiz-Ramírez](#), [Everardo López-Romero](#)^{*}

Posted Date: 4 March 2025

doi: 10.20944/preprints202503.0285.v1

Keywords: antibacterials; MDR; novel approaches



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

Novel Antibacterial Approaches and Therapeutic Strategies

Gustavo A. Niño-Vega *, Jorge A. Ortiz-Ramirez and Everardo López-Romero *

Departamento de Biología, División de Ciencias Naturales y Exactas, Campus Guanajuato, Universidad de Guanajuato, Noria Alta s/n, col. Noria Alta, C.P. 36050, Gto. México 1

* Correspondence: gustavo.nino@ugto.mx (G.A.N.-V.); everlope@ugto.mx (E.L.-R.)

Abstract: The increase of multi-drug resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies suggested to combat the increasing challenges of multidrug-resistant (MDR) bacteria. New treatments recently developed involve targeting key processes involved in bacterial growth, such as riboswitches and proteolysis, and combination therapies to improve efficacy and minimize adverse effects. It also tackles the challenges of the Gram-negative bacterial outer membrane, stressing that novel strategies are needed to evade permeability barriers, efflux pumps, and resistance mechanisms. Other approaches, including phage therapy, AMPs, and AI in drug discovery, are also discussed as potential alternatives. Finally, this review points out the urgency for continued research and development (R&D), industry-academic partnerships, and financial engines to ensure that MDR microbes do not exceed the value of antibacterial therapies.

Keywords: antibacterials; MDR; novel approaches

1. Introduction

The failure to effectively treat infectious diseases owing to an increasing trend in antimicrobial resistance (AMR) stands out as an emerging threat to public health, resulting in increased morbidity and mortality rates, extended hospitalization time, and greater financial burden. In a recent analysis, it was estimated that drug-resistant infections by 88 pathogen-drug combinations caused 4.95 million deaths worldwide, 1.27 million (25%) out of which were due to AMR [1]. Particularly, the widespread use of antibiotics in human and veterinary medicine together with environmental pollution by residual antibacterial pharmaceuticals generate a serious concern in relation to the emergence and spread of multi-drug resistant (MDR) pathogens. Recently, the World Health Organization (WHO) has alerted of a "post-antibiotic era" where simple infections and minor injuries might once again become deadly threats [2]. Moreover, antibiotics used to fight these infections can also have negative side effects [3], as the drugs used to eliminate the infectious agents also affect beneficial microbiota leaving an urgent need to re-evaluate treatments in terms of their ability to specifically target pathogenic bacteria while conserving the necessary microbiota [3].

In hospitals, broad-spectrum antibacterials and invasive procedures contribute to the high prevalence of MDR microbes, particularly among immuno-compromised patients, creating unique surveillance challenges. Medical devices like catheters and ventilators act as colonization sites for bacteria that can cause hospital-associated infections [4]. Moreover, the nature of resistant strains capable of forming biofilms should be considered, as they are hard to eliminate and lead to spread and repeated infections [5]. Horizontal gene transfer (HGT) adds even more complexity to this problem since it enables the sharing of resistant genes among bacterial species, thereby facilitating the spread of resistance in healthcare settings and ecosystems [6–8]. To overcome this, there is a need for novel therapeutic strategies with better long-term effects.

Exploration for new antibacterial agents is turning the attention towards previously unexplored bacterial mechanisms such as riboswitches and caseinolytic protease (ClpP) systems in the fight against bacterial resistance. Their goal is to inhibit those pathogen survival pathways at lower risk for developing resistance [9,10]. In addition, repurposing existing or investigational drugs approved for non-antibacterial use has been an effective strategy for discovering new therapies [11]. Combination therapies (pairing antibiotics with antivirulence agents—quorum-sensing inhibitors or efflux pump blockers) can also enhance the therapeutic effect [12,13]. This structural barrier has converted the development of effective drugs against pathogenic Gram-negative bacteria into a real challenge. Most antibiotics are limited by their ability to penetrate cells effectively because they face a protective outer membrane (OM) present in these bacteria. To overcome this challenge, novel approaches are under development to either alter and render the bacterial membrane more permeable or facilitate targeted drug uptake [14–16].

Advancements in genomic technologies have opened avenues for novel antibacterial drug discovery by improving the identification of targets within bacterial genomes. The rapid evolution of molecular biology and sequencing technologies, such as whole-genome sequencing (WGS) and metagenomics, have paved the way for identifying new drug targets, anticipating resistance patterns, and designing personalized therapies [17].

However, despite having made significant strides in antibacterial research, there has been a substantial decline in novel antibiotic development and a simultaneous rise in bacterial resistance over the past three decades [18]. The economic disincentives to the pharmaceutical industry have decreased its R&D investment in the field. Antibacterial treatments are for temporary use only, leading to reduced long-term profitability compared with medications for chronic diseases. Also, new government regulations and high clinical trial costs make it harder to enter the market. While initiatives, including public funding for early-stage research and market-entry rewards for antibacterial agents, have been suggested to incentivize development, they have not yet promoted sufficient investment in novel R&D within the industry [19,20].

Here, we review current antibacterial approaches, recent therapeutic developments, and some of the future strategies needed to fight the worldwide problem of AMR.

2. Factors Contributing to the Increase in Bacterial Infections

One of the major causes managed by human medicine is antibiotic overuse, which is widely documented as a driver of bacterial resistance to antibiotics. Overusing antibiotics for viral infections, the non-judicious use of broad-spectrum antibiotics, and patients not completing their antibiotic course all create selective pressure, giving resistant bacteria a survival advantage [6]. Even low doses of antibiotics can act as a selective pressure for adaptation in bacteria, raising the likelihood of mutations in resistance genes and expediting the emergence of MDR bacteria in healthcare settings [4]. Infections acquired in these environments are considered the third leading cause of human death after cancer and heart disease. Horizontal gene transfer (HGT) is the primary biological mechanism contributing to the rising resistance in bacteria and plays a major role in the spread of antibiotic resistance genes (ARGs). Mobile genetic elements serve as vehicles for HGT in both hospital and environmental settings, increasing the burden of resistance [5]. The most common way for HGT to disseminate ARGs in bacteria is **conjugation**. In the conjugation process, a donor bacterium can transfer plasmids containing its resistance genes directly into a recipient through contact between the two, especially in settings with high bacterial density, such as hospital or agricultural environments [6]. Conjugative plasmids transport several ARGs originating MDR microbes [6]. Through **transformation**, bacteria can take up free DNA from their surroundings and acquire resistance genes. This frequently occurs in sites with a high abundance of dead bacterial cells, allowing ARGs to be taken up and incorporated into the genomes of living bacteria [7]. Another biological mechanism of HGT is **transduction**, where bacteriophages transport ARGs from one bacterium to another. Transduction is especially important in environments rich in bacteriophages, such as the human gut microbiome or wastewater treatment plants [8]. High levels of antibiotics favor the conjugation

frequency and expression of plasmid-carried conjugation-related genes (as seen in wastewater or agricultural runoffs). Sub-minimal inhibitory concentration (MIC) levels of antimicrobials such as meropenem and ciprofloxacin have been shown to markedly facilitate the horizontal plasmid-mediated transfer of resistance from *Klebsiella pneumoniae* and *Escherichia coli* [21].

While we understand the significance of HGT on increased resistance, managing its effects is still challenging. Microbial communities are diverse in environments such as wastewater treatment plants, hospitals, and, most importantly, the human gut, making tracking and controlling ARG transfers out of complex microbiomes extremely difficult. In addition, biofilms on biotic and abiotic surfaces help resistant bacteria survive and spread due to the persistence of ARGs in biofilms.

The application of antibiotics to livestock generates pools of resistant bacteria that can transfer ARGs to human pathogens through HGT. Animal health products and antibiotics are widely used in livestock as growth promoters or to prevent infection, creating reservoirs of resistant bacteria. These resilient microorganisms can spread to humans through direct contact, food items, and environmental contamination. Antibiotic-resistant microbes can spread across water and soil through agricultural runoffs containing resistant bacteria and antibiotics [22]. Resistant bacteria reservoirs are even made more complex as migratory birds, soil, and air [23]

Nosocomial infections are considered the third leading cause of death, after cancer and cardiovascular disease. Catheters and ventilators are common sources of contamination from bacteria. Thus, bacteria-harboring resistance genes survive and disseminate rapidly to immunocompromised patients in such environments [4]. More recently, a study monitored the transfer of plasmids that harbored ARGs between bacterial species within a hospital setting [7]. This movement of plasmids between bacteria is a significant factor in the rapid spread of resistance in hospitals [7]

HGT is also facilitated to a significant extent by the presence of non-antibiotic compounds like heavy metals, food preservatives, and pharmaceuticals. Silver nanoparticles commonly used in personal care products release silver ions into the environmental system and induce oxidative stress response of bacteria, further stimulating the transfer of plasmid [24] and facilitating conjugative transmission of ARGs. Likewise, well-known active pharmaceutical ingredients (APIs) such as the antidepressant fluoxetine and synthetic analgesics like acetaminophen promote ARG transfer with mechanisms involving increased permeability of the cell membrane and SOS response induction, activating DNA repair pathways that facilitate plasmid integration [21]. The increased membrane permeability, the stress responses, and an increased probability for intact HGT promote the dissemination of resistant microbes to environments beyond health care [25].

3. Search for Novel Targets and Therapies

Classical antibiotics act on essential bacterial processes, including cell wall synthesis (e.g., β -lactams), protein synthesis (e.g., aminoglycosides), and DNA replication (e.g., fluoroquinolones). Although effective, the rampant overprescription and abuse of these medications result in the emergence of resistant strains due to the selective pressure applied to the bacterial population owing to the transfer of the HGT elements [7]. Furthermore, such antibiotics commonly have toxicity and off-target effects when given in high doses or for a prolonged time, threatening their long-term effectiveness [26].

Instead, the new antibiotics are based on original bacterial processes that are important for survival and with less likely development of resistance. Riboswitches are non-coding RNA domains that detect specific target ligands and regulate gene expression in bacteria. A recent study targeting flavin mononucleotide (FMN), thiamine pyrophosphate (TPP), and glmS riboswitches with chimeric antisense oligonucleotides effectively resulted in the inhibition of bacterial growth but without exhibiting toxicity on human cell lines [9], representing a rational and selective action against bacteria such as *Staphylococcus aureus* and *Escherichia coli* that are substantial resistant pathogens [10]. Antibiotics in development target the bacterial caseinolytic protease (ClpP), essential for maintaining proper levels of protein homeostasis within bacteria, promoting their death. This class of antibiotics,

known as activators of self-compartmentalizing proteases (ACPs), has demonstrated activity against Gram-negative pathogens for which traditional antibiotics are ineffective, including the *Neisseria* species [10].

Combination therapies are one way to improve the effectiveness of both old and new antibiotics. Combined treatment of gallium (a siderophore quencher) and furanone C-30 (a quorum-sensing blocker) with antibiotics colistin and ciprofloxacin have been demonstrated to restore sensitivity against *Pseudomonas aeruginosa* [12]. However, β -lactams are still ineffective in combatting resistant bacteria due to the production of β -lactamase by these microorganisms. A combination of meropenem-vaborbactam, consisting of a carbapenem and a β -lactamase inhibitor, can overcome this resistance mechanism and restore activity against carbapenem-resistant *Enterobacterales* [13].

Antibacterials that target bacterial membranes represent an alternative mode of action with the potential to avert resistance development. PQ401, a new class of neutral diarylurea compounds, displays broad-spectrum activity against antibiotic-resistant and antibiotic-tolerant *S. aureus*. PQ401 circumvents an antibiotic limitation where cross-resistance to membrane-active agents like polymyxins has been observed [27] by causing select disruption of bacterial membranes.

Novel antibiotics with less toxicity and improved safety profiles are being rolled out. The replacement of l-Val with d-Val significantly enhanced the stability and safety of engineered antimicrobial peptides (AMPs) by presenting a potent activity against MDR bacteria in respiratory infections while exhibiting a 4-fold improvement in safety compared to earlier versions, showing less toxicity to human cells [28].

4. Challenges in Developing Antibiotics Targeting Gram-Negative Outer Membranes

The unique structure of the cell envelope in Gram-negative bacteria contains an extra outer membrane (OM) that restricts drug permeability. This prevents many antibiotics from accessing their intracellular targets and plays an important role in intrinsic and acquired antibiotic resistance, primarily linked to permeability barriers, efflux pumps, and resistance mechanisms.

4.1. The Outer Membrane as a Permeability Barrier

The outer leaflet of the outer membrane contains lipopolysaccharides (LPS), whereas the inner leaflet is composed of phospholipids, both of which form a hydrophobic and impermeable barrier to many antibiotics against Gram-negative bacteria. This low permeability is a key characteristic by which Gram-negative bacteria are inherently more resistant to antibiotics than Gram-positive [29]. For antibiotics to reach their intracytoplasmic targets, they must cross this OM. Yet only a narrow range of chemical entities can do so due to the barrier's preference for small, hydrophilic compounds that permeate through porins.

4.2. Porins and Antibiotic Entry

Porins (e.g., *E. coli* OmpF) function as channels that allow for passive diffusion of hydrophilic molecules, including some antibiotics, into the cell. Nonetheless, porin mutations result in a decrease in expression and/or conformational alteration, limiting the entry of antibiotics. Furthermore, porins have dynamic open-closed states to control antibiotic permeability, and thus, drug molecules cannot reach target sites inside the cell stably [30].

4.3. Efflux Pumps

Furthermore, even when antibiotics penetrate into OM, Gram-negative bacteria can express efflux pumps-membrane proteins that maintain their intracellular concentration of antibiotics at a non-lethal level. Pumps in this group (e.g., AcrAB-TolC system in *E. coli*) decrease the intracellular concentration of antibiotics, especially the lipophilic or bulkier ones, and contribute to multidrug resistance [15].

4.4. Targeting Outer Membrane Proteins

Despite being an efficient approach to overcome resistance, antibiotics that act on essential players in the OM, for example, β -barrel assembly machinery (BAM complex) and lipopolysaccharide(s) transport machinery (Lpt), are relatively new. The BAM complex inserts β -barrel proteins into the OM, whereas Lpt transports lipopolysaccharide (LPS) to the OM. These systems are also the target of inhibitors that permeabilize membranes and increase the susceptibility of bacteria to antibiotics [14]. A primary challenge in designing these inhibitors is that they must circumvent efflux pumps and reach high local concentrations at their sites of action. A range of compounds that repress OM assembly are non-soluble by efflux systems, necessitating combination procedures or adjustments to increase their intracellular retention [31].

A promising broad-spectrum antibacterial active against Gram-negative bacteria is darobactin A, which acts on the OM protein BamA, binding this target in the periplasm and impairing protein folding and integration. Thus, a major advantage of this antibacterial is to circumvent the need to pass over the permeability barrier [32]. It was recently shown that natural darobactin A, obtained from an entomopathogenic bacterium, can be processed to yield darobactins D (D22) and 69 (D69). D22 was active *in vivo* against murine infections of *Pseudomonas aeruginosa* and *E. coli* and rescued zebrafish embryos infected with *A. baumannii* [33].

Chemical perturbants such as MAC-0568743 disrupt the OM while selectively preserving the inner membrane, enabling antibiotics, such as vancomycin, to penetrate resistant Gram-negative bacteria [34]. These OM disruptors work in tandem with common antibiotics, improving their effectiveness against resistant strains.

Novel approaches target the OM to breach its integrity, permitting antibiotics to permeate and exert their effects more effectively [35]. SPR741 is a novel polymyxin B analog that permeabilizes explicitly the outer membrane while leaving the inner membrane intact, enabling antibiotics to act on their intracellular targets more efficiently [36]. OM disruptors and Gram-positive active antibacterials have been reported to be effective against murine infections caused by *A. baumannii*, *Klebsiella pneumoniae*, and *E. coli* [35]. Due to the significance of LPS in the outer membrane of Gram-negative bacteria as an outer component, it maintains membrane integrity and is antibiotic penetration-resistant. Disruption of the OM has been proposed as a promising strategy by targeting LPS biosynthesis and transport, specifically the enzymes involved in both biological processes [37].

4.5. Importance of Disrupting Transport and Synthesis of Lipoproteins as an Antibacterial Strategy

This emerging approach reduces the robustness of MDR Gram-negative bacteria by disrupting OM lipoprotein transport and biogenesis. These proteins are acylated, anchored into the inner membrane, and transported to the OM by dedicated transport systems, such as the ATP-binding cassette (ABC) transporter LolCDE. Lipoproteins play fundamental roles in OM assembly, nutrient uptake, and resistance to environmental stress and antibiotics [38]. Consequently, pathogenic bacteria have developed decreased reliance on the lipoprotein transport pathway, which is now gaining traction as a valuable target for novel antibacterial therapies [31].

The Lol (Localization of lipoproteins) pathway constituting the LolCDE transporter is required to extract lipoproteins from the inner membrane and convey them to the OM. Key components of the Lol pathway include:

- **LolCDE Complex** — The ATP-binding cassette (ABC) transporter LolCDE extracts lipoproteins from the inner membrane and is critical for their subsequent delivery to the OM. Recent structural studies have shed light on the transport mechanism of lipoproteins by LolCDE, involving significant rearrangements in the transmembrane helices causing large-scale "extrusion" movement of lipoprotein from the membrane [36]. Muñoz et al. recently designed a novel class of selective and potential gram-negative pathogenic bacteria active antibiotic called lolamicin [3]. For drug design, they targeted the essential LolCDE complex that mediates the transport of OM-specific lipoproteins to the periplasm via the cytoplasmic membrane [39]. Lolamicin displayed activity against an MDR-isolates collection of 130 strains via efficacy against

multiple murine pneumonia and septicemia models as well as protection against *C. difficile* gut infection in a mouse model of microbiome [5]. They suggested that lolamicin is active against Gram-negative pathogenic bacteria but inactive toward commensals (both Gram-positive and -negative) based on low sequence homology between the two classes of organisms. Thus, lolamicin seems to be at least a potential candidate for testing and possibly application against human infections.

- Chaperones: LolA and LolB are periplasmic chaperone proteins that transfer lipoproteins across the periplasm and insert them into OM. If either LolA or LolB is disrupted, lipoproteins become mislocalized, and defects in OM assembly arise [40].
- Inhibition of Lipoprotein Diacylglyceryl Transferase (Lgt): It catalyzes the first step in lipoprotein biogenesis, where it acylates lipoproteins in the inner membrane. Lgt inhibitors like G2824 mess up OM permeability to make bacteria more susceptible to serum killing and antibiotics. Importantly, these inhibitors show activity against strains resistant to other lipoprotein pathway inhibitors [41].

While interfering with lipoprotein transport provides a powerful approach, resistance mechanisms developed by bacteria counteract these inhibitors. Deleting the *lpp* gene, which encodes Braun's lipoprotein in Gram-negative bacteria, circumvents inhibiting downstream steps in lipoprotein biosynthesis. On the other hand, moving down the path and targeting later steps, as with inhibitors against Lgt itself, seems less susceptible to this resistance mechanism [42], making them more favorable for clinical development.

Inhibiting lipoprotein biogenesis or transport induces bacteria's sensitivity to current antibiotics and may repurpose previously inadequate drugs for use against MDR pathogens. This method is particularly encouraging for infections caused by *P. aeruginosa*, *A. baumannii*, and *K. pneumoniae*, which have shown resistance to traditional antibiotics [31].

Stress response systems regulate lipoprotein trafficking in bacteria. In *E. coli*, the Cpx system monitors the delivery of OM lipoproteins and activates a stress response to promote protection against the so-called trafficking defects. Targeting this system can make lipoprotein transport inhibitors more efficacious, as this is essential for bacterial survival in the presence of lipoprotein trafficking indisposition [42].

4.6. Chemical Space Limitations

The process of discovering new antibiotics is especially hindered now with the limited diversity in chemical libraries traditionally used for drug discovery. Most compounds are optimized for Gram-positive pathogens and lack the required physicochemical properties for penetrating the OM of Gram-negative pathogens. New strategies attempt to broaden the chemical space by finding matrix molecules that can go in through the OM and not get extruded out by efflux pumps. Optimizing these parameters for higher permeability, coupled with the need to maintain optimal hydrophobicity and charge so the compound can pass through porins and enter into cells, has been an avenue pursued in recent work [15].

4.7. These Complexities Pose Their Own Challenges in Clinical Development

The potential for OM disruptors to cause toxicity is one of the key challenges in developing these findings into clinically relevant treatments. Murepavadin, a Lpt system inhibitor that showed promise in preventing *P. aeruginosa* pathogenesis, was shown to be effective but discontinued due to the observed nephrotoxicity during clinical trials [34]. This provides a rationale for why these two considerations must change — namely, all mechanisms that disrupt bacterial membranes may also adversely affect mammalian cell membranes, making it difficult to find drugs with enough specificity and safety.

Combination therapies against Gram-negative OM will be required in the future. Treatment with OM disruptors and intracellular-targeting antibiotics can synergistically increase drug efficacies while decreasing the likelihood of resistance emergence. This is also exemplified by other

combination therapies that use OM perturbation to help antibiotics, such as β -lactams and glycopeptides, access their targets in Gram-negative bacteria [43]. Using efflux and permeability predictions in medicinal chemistry can enable the rational design of updated antibiotics [16]. Finally, the inhibitors of drugs that target resistance mechanisms (e.g., viz efflux pump, β -lactamase), when developing along with agents disrupting the OM, can reduce antibiotic resistance and retain current antibiotics viability, gaining time for novel alternative class antibacterial development [44].

5. Emerging Antibiotics and Strategies

In recent years, several new compounds and strategies have emerged. These new antibiotics include novel classes and derivatives targeting resistant pathogens, innovative delivery systems, and combination therapies (Table 1).

Table 1. New antibiotics and strategies.

Antibiotic/Strategy	Class/Type	Target Pathogens	Mechanism of Action	Key Notes
Eravacycline	Tetracycline	Gram-positive and	Overcomes tetracycline	Broad-spectrum
	derivative	Gram-negative bacteria, including <i>A. baumannii</i> , <i>E. coli</i>	resistance mechanisms like efflux pumps and ribosomal protection proteins	activity against MDR bacteria. Approved for complicated intra-abdominal infections.
Cefiderocol	Siderophore cephalosporin	Carbapenem-resistant <i>Enterobacterales</i> , <i>P. aeruginosa</i>	Uses bacterial iron transport system (siderophore mechanism) to penetrate Gram-negative bacteria and bypass resistance mechanisms.	Effective against Gram-negative bacteria.
Plazomicin	Aminoglycoside derivative	MDR <i>Enterobacterales</i> , including carbapenemase producers	Evades aminoglycoside-modifying enzymes	Approved for complicated UTIs.
Delafloxacin	Fluoroquinolone	Gram-positive and Gram-negative bacteria, including MRSA	Increased potency in acidic environments; effective for skin and soft tissue infections.	Effective in acidic environments found at infection sites.
Meropenem-Vaborbactam	β -Lactam/ β -Lactamase Inhibitor	Carbapenem-resistant <i>Enterobacterales</i>	Vaborbactam inhibits serine carbapenemases, restoring meropenem's activity against resistant strains.	Approved for complicated UTIs
Corbomycin	Glycopeptide	Gram-positive pathogens, including MRSA	Binds to bacterial cell wall, preventing autolysin activity, which differs	Unique mechanism with

			from traditional glycopeptides like vancomycin.	low resistance development.
Nanomaterials and Drug Delivery Systems	Nanotechnology-based strategy	Various resistant pathogens	Nanoparticles improve antibiotic delivery, increase bacterial internalization, and enhance biofilm penetration.	Enhances antibiotic effectiveness and reduces dosage requirements.
MD-124	Antibiotic potentiator	Drug-resistant Gram-negative bacteria	Permeabilizes bacterial outer membrane, enhancing antibiotic efficacy (e.g., colistin).	Potentiators offer a cost-effective strategy to combat resistance.
Bacteriophage Therapy	Phage therapy	Antibiotic-resistant bacteria (<i>P. aeruginosa</i> in CF patients)	Use bacteriophages (viruses) to target and destroy specific bacterial pathogens.	Alternative to traditional antibiotics, with promising results in personalized medicine approaches.

5.1. Derivatives of Tetracycline (Eravacycline)

Eravacycline, a new synthetic tetracycline derivative recently approved for treating complicated intra-abdominal infections, has broad-spectrum activity against Gram-positive and Gram-negative bacteria, including MDR strains of *A. baumannii* and *E. coli*. Eravacycline was designed to avoid the most common tetracycline resistance mechanisms, such as efflux pumps and ribosomal protection proteins [45,46].

5.2. Siderophore Cephalosporins (Cefiderocol)

Cefiderocol: A novel cephalosporin that has a siderophore entry mechanism whereby it hijacks the bacterial iron transport system to enter through the outer membrane of Gram-negative bacteria. Cefiderocol avoids existing resistance mechanisms such as porin mutations and efflux pumps, making it highly effective for carbapenem-resistant *Enterobacterales* and *P. aeruginosa* [47,48].

5.3. Aminoglycoside Derivatives (Plazomicin)

Plazomicin is a next-generation aminoglycoside with reduced susceptibility to aminoglycoside-modifying enzymes, the most prevalent resistance mechanism to this class of antibiotics. It is indicated for complicated urinary tract infections (UTIs) and demonstrates in vitro potency against MDR *Enterobacterales*, including carbapenemase-producing strains [49–51].

5.4. Fluoroquinolones(Delafloxacin)

Delafloxacin (DLX) is a novel broad-spectrum fluoroquinolone recently discovered to have activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant *S.*

aureus (MRSA). It displays enhanced activity in acidic environments, such as those found at infection sites, and is effective for skin and soft tissue infections [52,53].

5.5. New β -Lactam/ β -Lactamase Inhibitor Combinations (Meropenem-Vaborbactam)

Meropenem-vaborbactam is a combination therapy of the carbapenem meropenem with the β -lactamase inhibitor vaborbactam that inhibits serine carbapenemases and restores activity to meropenem for use against carbapenem-resistant *Enterobacterales*. It is indicated for complicated UTIs, and it is a last-resort therapy against carbapenem-resistant bacteria [13].

5.6. New Glycopeptides (Corbomycin)

Corbomycin is a new glycopeptide that binds the bacterial cell wall to inhibit autolysins-mediated peptidoglycan remodeling during bacterial growth. Such action is distinguishable from typical glycopeptides such as vancomycin and has low rates of resistance emergence. It has been proven effective against MRSA and other resistant Gram-positive pathogens [54].

5.7. Nanomaterials in the Context of the Drug Delivery

Recently, nanotechnology has emerged as a novel approach for optimal antibiotic delivery and combatting resistance. Nanoparticles would enhance antibiotics' pharmacokinetics, improve bacterial cell internalization, and facilitate biofilm penetration. These drug delivery platforms decrease the development of resistance by improving effective targeting, leading to a lower dose requirement of antibiotics. Recent developments in nanotechnology involve using polymer-based and inorganic nanoparticles as carriers for traditional antibiotics, improving their efficacy against resistant pathogens [55].

5.8. MD-124: Antibiotic Potentiator

MD-124 is an oral small-molecule adjuvant, re-establishing (in the context of current antibiotic therapies) Gram-negative drug resistance to clinically relevant antibiotics. MD-124 acts synergistically with antibiotics such as colistin against bacteria and restores susceptibility in carbapenem-resistant strains by selectively permeabilizing the OM. Antibiotic potentiators like MD-124 fight resistance without developing new antibiotics [43].

5.9. Bacteriophage Therapy

Viruses that infect bacterial pathogens, known as bacteriophages, are an alternative to traditional antibiotics, which still need advancement via design implementing *in vivo* and *ex vivo*-based approaches. The one that has gotten some attention is phage therapy, which shows promise in the fight against antibiotic-resistant bacteria, especially under personalized medicine circumstances. Similar studies are being conducted with phages against other pathogens, such as the therapeutic use of phages to treat drug-resistant *P. aeruginosa* infections in cystic fibrosis patients [56].

6. Post-Genomic Era Antibacterial Drug Discovery

The post-genomics era has uncovered many new targets for antibiotic drug discovery and developed strategies to combat the growing threat of resistance against current antibacterials. Three of these targets, discovered through advances in bacterial genomics and molecular biology, included bacterial signal transduction systems, lipid biosynthesis pathways, and structural components essential for bacterial viability (Table 2).

6.1. Histidine Kinases in Two-Component (TCS) and Quorum Sensing Systems

Bacterial two-component systems (TCSs), with histidine kinases (HKs) as integral components, play a critical role in bacterial adaptation to environmental stress, such as antibiotic exposure.

Histidine kinases are involved in bacterial signaling pathways that mediate antibiotic resistance, and they can be targeted to disrupt these pathways. Due to the absence of TCSs in humans, HKs are an attractive target for selective inhibition of bacterial growth without threat to human cells. Recent work has shown that HK inhibition can affect bacterial signaling to render pathogens less virulent. HKs possess an ATP-binding domain, which is highly conserved between bacterial species and offers a promising target for broad-spectrum antimicrobial activity [57]. Moreover, HKs also serve as the target of novel specific drugs to treat infections caused by MDR organisms, such as *S. aureus* and *A. baumannii* [58].

Other protein kinases, notably those that play roles in bacterial signaling pathways, provide attractive drug targets. Serine/threonine kinases are important pathogen virulence factors that regulate bacterial growth, and inhibitors of these enzymes in *Mycobacterium tuberculosis* may be useful candidates for treating tuberculosis. Most recent work has identified compounds that impede these kinases from their function and kill the organism in animal models [59]. A comprehensive survey of histidine kinase (HK) inhibitors has been performed, providing information on structural classifications, chemical structures, IC₅₀ & MIC values, antivirulence properties, and exploring domains for HK targets, including the ATP-binding domain, HK sensors, histidine phosphorylation domain, and dimerization [58].

Quorum sensing (QS) is achieved by a cell-to-cell communication system allowing Gram-positive and Gram-negative bacteria to regulate gene expression, including virulence factor production, as a function of population density. The inhibitory effect on the quorum sensing disrupts these processes and leads to less bacterial pathogenicity and biofilm formation, which is also generally resistant to antibiotics. Accordingly, it has been shown that inhibiting the AgrC histidine kinase in the quorum-sensing system of *S. aureus* reduces virulence and biofilm formation [60]. The VraTSR three-component system is another important *S. aureus* system that recognizes cell wall damage after antibiotic exposure. Compounds that inhibit the VraTSR system have decreased the survival of this bacterium exposed to cell wall-targeting antibiotics and could be useful for combination therapies [61].

6.2. Lipid Biosynthesis Pathways

The OM of Gram-negative bacteria contains an important element, lipid A. Targeting its biosynthetic pathway allows for the OM to be compromised, making the cells more susceptible to antibiotics. Over the past eight years, significant effort has been directed toward other enzymes in the lipid A biosynthesis, such as LpxC and LpxH, the second and fourth enzymes of the Raetz pathway. LpxC inhibitors, like LPC-233, are potent bactericidal agents against MDR pathogens without the cardiovascular toxicity of early LpxC inhibitors [62]. Inactivating other LpxC inhibitors has been shown to inhibit growth in clinically relevant Gram-negative pathogens, including *P. aeruginosa* and *K. pneumoniae* [63]. In addition, inhibition of LpxH accumulates toxic lipid A intermediates and thus kills the bacteria due to an essential step in the fatty acid mobilization of lipid A biosynthesis. Inhibition of both LpxC and LpxH, which work in tandem with lipid A biosynthesis, thus provides a dual-action inhibition strategy that represents a powerful tool against MDR infections [64].

One such strategy has targeted agents interfering with lipid II, an important component of bacterial cell wall biosynthesis. An example of such a synergistic approach is the combination of Lipid II-targeting antibiotics with outer membrane-acting peptides to potentiate their activity against Gram-negative pathogens [65].

Table 2. New targets for antibacterial drug development in the post-genomic era.

Target	Description	Mechanism of Action	Key Examples/Notes
Histidine Kinases (HKs)	Part of Two-Component Systems (TCS) involved in bacterial stress response and antibiotic resistance	Inhibition of HKs disrupts bacterial signaling pathways, reducing pathogenicity and virulence.	- Targeting the ATP-binding domain of HKs has shown broad-spectrum antimicrobial activity [55] - Effective against MRSA and <i>A. baumannii</i> [56].
Quorum Sensing Systems	Bacterial communication system regulating virulence and biofilm formation.	Inhibiting quorum sensing reduces pathogenicity and biofilm formation.	- AgrC histidine kinase inhibition reduces virulence and biofilm in <i>S. aureus</i> [60]
Lipid Biosynthesis Pathways	Essential for bacterial membrane integrity in Gram-negative bacteria	Inhibition of lipid A biosynthesis weakens bacterial outer membrane, increasing susceptibility to antibiotics.	- LpxC inhibitors (e.g., LPC-233) show potent activity against MDR pathogens without toxicity [62]. - LpxH inhibition causes toxic lipid accumulation [64]
Protein Synthesis Inhibition	Critical for bacterial survival and growth.	Inhibition of ribosome function disrupts protein synthesis.	- Spermine-conjugated lipopeptides inhibit protein synthesis in <i>E. coli</i> [66] - Antimicrobial peptides target ribosomes in MDR strains [65]
DNA Gyrase and Topoisomerase	Enzymes essential for bacterial DNA replication.	Inhibition of DNA gyrase and topoisomerase prevents bacterial replication.	- 1,2,4-oxadiazole-chalcone hybrids show activity against Gram-positive and Gram-negative bacteria by inhibiting DNA gyrase [67]
Protein Kinase Inhibitors	Enzymes involved in bacterial growth and virulence, especially in <i>M. tuberculosis</i> .	Inhibition of serine/threonine kinases disrupts bacterial signaling and growth.	- Kinase inhibitors show efficacy in controlling tuberculosis [59]
Peptidoglycan and Membrane Targets	Peptidoglycan layer is essential for bacterial cell wall integrity.	Disruption of peptidoglycan weakens the bacterial cell wall, leading to bacterial death.	- Oligomeric structures disrupt the peptidoglycan layer in Gram-positive bacteria like <i>S. aureus</i> [68]

6.3. Protein Synthesis Inhibition

Since protein synthesis is a fundamental process for bacterial life, the ribosome has proven to be a successful target for antibiotic development. However, the most recent work centers on spermine-conjugated short proline-rich lipopeptides that target and block protein synthesis in *E. coli* without compromising bacterial membrane integrity. These lipopeptides exhibit broad-spectrum activity and synergy with conventional antibiotics, particularly in MDR strains [66]. Recent work has also focused on designing antimicrobial peptides that target the prokaryotic ribosome, preventing protein synthesis and showing high potency against MDR *S. aureus* and *E. coli* [65].

6.4. Inhibitors of DNA Gyrase and Topoisomerase

During bacterial DNA replication, two key enzymes important for the process include DNA gyrase and topoisomerase IV. Fluoroquinolones, drugs that target these enzymes, have enjoyed great success but are now facing a vigorous counterattack in the form of resistance. New compounds are developing that inhibit DNA gyrase by novel mechanisms. The synthesis of 1,2,4-oxadiazole-chalcone hybrids was reported, and high Gram-positive and Gram-negative antibacterial activity was observed through DNA gyrase inhibition [67].

6.5. Targets in Bacterial Peptidoglycan and Membrane.

Work has thus far centered around synthetic oligomers that cause peptidoglycan disruption, targeting Gram-positive pathogens such as *S. aureus*. The materials' high antibacterial activity provides good reference significance for their use in functional materials against drug-resistant bacteria [68].

7. What's New in Bacterial Genome Sequencing

The emergence of bacterial genome sequencing has transformed our perception of how bacteria function biochemically and molecularly, how they respond to antibiotics (clinical resistances), and how they reveal novel targets for new antibiotics. Whole-genome sequencing (WGS) and metagenomics have since emerged as integral components of clinical diagnostics and drug discovery. Here, we discuss some major breakthroughs in bacterial genome sequencing and their relevance for tracking antibiotic resistance and developing new antibiotics.

7.1. Predicting Antibiotic Resistance Using Whole-Genome Sequencing

Whole-genome sequencing is now an essential tool for predicting bacterial pathogens' antibiotic-resistance genes (ARGs). Sequencing genomes of drug-resistant bacteria can detect ARGs, determine transmission potential, and predict resistance profiles at the clinical level.

- **Antimicrobial Resistance Prediction:** The use of WGS data to predict resistance phenotypes (particularly in Gram-negative bacteria) is currently being explored. Machine learning models developed on WGS data can predict resistance to multiple antibiotics with a high degree of accuracy, enabling real-time clinical decisions and potentially swift treatment tailored to the group's type and required level of therapy [69]. This could provide *in silico* antibiograms, thereby assisting the correlative management of resistant infections.
- **Genomic Databases for Resistance Genes:** Novel tools such as BacAnt and ARTS are available for genome annotation regarding antimicrobial resistance genes (ARGs) and mobile genetic elements (MGEs), which are crucial for monitoring the transmission of resistance genes. Such bioinformatics platforms automate the detection of ARGs and MGEs, aiding epidemiological studies and resistance monitoring [70].

7.2. Discovery of New Antibiotics Through Genome Mining

The advent of genome sequencing technology has unraveled biosynthetic gene clusters (BGCs) responsible for generating novel secondary metabolites, some with promising antibiotic activity. Identifying previously uncharacterized BGCs in mined bacterial genomes can lead to discovering potential new antibiotic compounds.

- **Triggering of Silent Gene Clusters:** Many genes responsible for producing antibiotics remain silent during normal laboratory conditions. With improvements in genome mining approaches such as CRISPR / gene editing technologies, these silent clusters have been induced for expression, producing, e.g., lignin or lactobacilli [17].
- **Drug Discovery with Comparative Genomics:** Over the years, based on comparative genomic approaches, highly conserved genes across bacterial species are essential as novel drug targets. Despite the inherent redundancy in secondary metabolite gene clusters, it has been possible to connect several novel chemical structures with antibacterial activity to their respective gene clusters for rational antibiotic design [71].

7.3. A Novel Approach for Antibiotic Resistance Surveillance - Metagenomics

Research based on metagenomic sequencing has been performed in various environmental contexts, including hospitals, soil, and the human gut, to investigate microbial communities and resistomes (the collective set of all ARGs). Such an approach is useful for tracing the environmental sources of resistance genes, as well as how human activity drives the dissemination of antibiotic-resistant bacteria.

- **Environmental Resistome Studies:** Most ARGs are present in environmental bacteria long before they can be recovered from clinical pathogens. Methods such as metagenomics and metatranscriptomics could further increase the detection of unknown ARGs in bacteria that may not be culturable [72].
- **Predictive Surveillance for Emerging Resistance** — High-throughput genomic sequencing integrated with functional genomics enables the observation of resistance genes across space and time. Such predictive surveillance is necessary to detect and mitigate emerging resistance threats early enough [73].

7.4. Third-Generation Sequencing and Producing Complete Genomes

The emergence of third-generation sequencing platforms (e.g., PacBio and Oxford Nanopore), which can assemble entire bacterial genomes (including plasmids and mobile genetic elements coding for ARGs), have facilitated a better resolution to unveil the resistance mechanisms involved in MDR organisms. Such technologies address the limitations of short-read sequencing, which fails to resolve repetitive elements and insertion sequences that are key to understanding resistance mechanisms. Recent advances have created gold-standard protocols for using third-generation sequencing to assemble bacterial genomes and identify ARGs within antibiotic-resistant strains. Methods based on DNA extraction with magnetic beads followed by long-read sequencing are suitable for plasmid reconstruction that carries resistance genes [74]. They help to reconstruct the genetic context and transmission dynamics of ARGs.

8. Applying Genomic Advances to Improve Public Health

Genome sequencing has been applied to rapidly detect resistant pathogens and guide treatment in clinical settings. Nowadays, WGS is utilized to build resistance profiles of clinical isolates, which can help with effective antibiotic selection and circumvent broad-spectrum antibiotics. The information on resistance mechanisms available through genome sequencing of clinical isolates will allow targeted treatment regimens. It is extremely useful in the case of MDR organisms, where rapid diagnostics are critical to patient outcomes. To this end, machine-learning models leveraging these

genomic data are being trained to predict antimicrobial resistance and optimize therapy for patients infected with resistant pathogens [75].

8.1. Monitoring Antimicrobial Resistance Using Genomics

WGS has changed AMR surveillance, making it possible to discriminate accurately the resistance gene and its passing into bacterial populations. The genotyping approach aids in the detection of new resistant variants that can best help formulate effective containing strategies.

- AMR Surveillance platforms in clinical settings: Several bioinformatics platforms have been developed, such as ResFinder, CARD, and MEGARes, to catalog ARGs and their dissemination through clinical and environmental samples. These enable real-time tracking of resistance mechanisms and have become an integral aspect of global surveillance [76]. *In vitro* activity against *P. aeruginosa* and *Citrobacter* spp. demonstrated the potential of nanopore sequencing for monitoring plasmid dissemination and resistance gene development during hospital outbreaks, which allows rapid action to stop the spread of resistant strains [77].
- Metagenomics, applied to environmental samples and animal habitats: Metagenomic approaches for environmental and animal habitats are increasingly being used to identify reservoirs of ARGs that could transfer to human pathogens. Thus, understanding the environmental transmission routes/pathways of antibiotic resistance is essential, and surveillance programs that incorporate environmental sampling are needed for identifying potential community sources [78]. Genomics is also being utilized for the detection of emerging pathogens and their antibiotic resistance profiles in populations. Projecting genomic diversity onto genotype-based diagnostics provides a more streamlined pathogen surveillance strategy than random sampling and can improve the identification of new resistance variants in pathogens like *Neisseria gonorrhoeae* [79].

8.2. Improving Detection and Response to Outbreaks

Outbreak management needs genomic sequencing. It enables public health authorities to help identify sources of outbreaks and quickly trace the transmission of infections.

- Outbreak Investigations and Responses: WGS has been important to multiple outbreak investigations, allowing strain differentiation between outbreak and sporadic isolates. This ability provides for better identification of transmission chains, such as WGS-based tracking of *Staphylococcus pseudintermedius* infections in companion animals and their connections to pathogens in humans [80].
- Real-Time Genomic Tracking: With portable sequencing technologies like nanopore sequencing, bacterial infections can be tracked in real-time from a genomic perspective. These technologies are also advantageous in resource-limited settings and public health emergencies when genomic data can be used critically to guide interventions [77].

8.3. The advent of Personalized Medicine and Precision Public Health

Genomic tools have opened doors to personalized medicine in which the therapy can be adapted based on host genetics and pathogen identity. In a recent study, WGS, alongside machine learning, was employed to inform resistance-minimizing treatment optimization using patient-specific risk assessment for efficiency in the urinary tract and wound infections [81]. WGS now plays an integral role in precision public health by forecasting the antimicrobial resistance potential of clinical pathogens before therapy. Genomic prediction of resistance to key antibiotics such as meropenem and ciprofloxacin based on WGS improved treatment outcomes by ensuring appropriate patient therapy [69].

8.4. One Health Surveillance

The One Health approach acknowledges human, animal, and environmental health together so it can be used to battle antimicrobial resistance as part of the global public health challenges. Genomic technologies allow the interdisciplinary monitoring of pathogens and ARGs in the environment, fostering One Health approaches. For example, genomic surveillance of *Salmonella* and *E. coli* animal pathogens has demonstrated considerable genetic overlap between animal and human infections, suggesting the need for integrated One Health surveillance systems. Integrating veterinary diagnostic data into national surveillance programs has been shown to enhance the detection of resistance trends in companion and food animals that may have significant implications for human health [82].

9. AI for Antibiotic Discovery

AI has become a new tool with great potential to identify new drug targets and antibacterial agents against bacterial resistance [83,84], as this innovative approach allows us to analyze large datasets that outperform traditional methods and allow discovering complicated associations of biological information (e.g., genomic or transcriptomic) with chemical/physical data using learning algorithms and artificial neural networks [85]. Also, it helps to re-purpose the available drugs that were earlier developed for other diseases or infections as a treatment for drug-resistant infections [86]. For example, an MIT research team trained a deep-learning neural network to evaluate over 100 million compounds in their database [87]. Halicin, initially developed as a diabetes medication, was revealed by following this method. Halicin, a small molecule with a different backbone than traditional antibiotics, shows bactericidal activity against Gram-negative pathogens that would otherwise be resistant to all available antibiotics, like *M. tuberculosis* and *Enterobacteriaceae*. It has also proved effective against *Clostridioides difficile* and MDR *A. baumannii* in murine infection models, highlighting the advantages of deep-learning approaches for novel targets and antibiotics [86].

9.1. Small-Molecule Antibiotics

These AI-based screening models minimize the extensive and costly *in vitro* experiments that prevent scientists from comprehensively surveying existing and repurposing novel compounds, facilitating economic identification of viable antibiotics. AI has been particularly useful for optimizing the process of small molecule discovery – a mainstay in antibiotic development. Antimicrobial compounds have been identified using machine-learning models to screen large chemical libraries [88]. Novel Small Molecule Optimization using Generative Techniques such as Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs) are among some of the techniques employed to design novel small molecules specific to certain antimicrobial properties. Models that generate chemical structures based on specific activity (such as for activity against a given bacterial pathogen) can optimize molecules for bioavailability and toxicity [89].

9.2. Discovery of Antimicrobial Peptides (AMPs)

Several deep-learning models have been created to expedite AMP discoveries that are capable of predicting the antimicrobial activity of peptide sequences. The AMP predictive deep learning model (AMPs-Net) presented superior predictions of peptide activities than the traditional mechanisms and allowed the identification of new AMPs with potential strong antibacterial capabilities [90]. The pairing of AI with molecular dynamics simulations allows for discovering AMPs that show high therapeutic value and increased stability. In a recent study, a deep learning model was used to mine large metagenomic datasets and built AMPSphere – an exhaustive catalog of ~900,000 non-redundant peptides, many previously untested experimentally. This strategy has identified peptides with potent *in vitro* and *in vivo* activity against drug-resistant pathogens [91].

9.3. Predicting Antibiotic Resistance

Prediction of antibiotic susceptibility phenotypes through analysis of bacterial WGSs is a promising approach to facilitate the development of targeted therapies. Models to Predict Resistance in *Salmonella* spp. and *N. gonorrhoeae* show 90% accuracy [29]. Machine learning can discern subtle patterns in genomic datasets, identify novel genetic mutations associated with antibiotic resistance mechanisms, and help lay the groundwork for specific therapies [92].

9.4. AI and Antibacterial Combination Treatments

Other models give rise to synergistic drug combinations that boost antibiotic activity. They also can analyze databases of drug interactions and resistance mechanisms and explore combinations that could be more effective in collaboration than when acting alone [93]. This is especially useful for returning older antibiotics and other agents against resistant strains. Recent advances in system biology and artificial intelligence have made it possible to take metabolic pathways through which bacteria process drugs into account, thereby predicting and leading researchers toward the optimal combinations of drugs that will best impact bacterial growth and survival [94]. Computational models such as these facilitate the discovery of new drug pairs to lower resistance development [94].

9.5. Mechanism of Action (MOA) Prediction

Because drug combinations have complex interactions affecting multiple bacterial pathways simultaneously, they are excellent candidates for AI-based approaches to machine learning and clinical prediction that elucidate the MOA of such drugs. By analyzing transcriptomic and proteomic data, they can predict the mechanism of action of novel and existing antibiotics. These models explain the interactions of antibiotics with bacterial targets and the cellular behaviors of bacteria [95].

9.6. Advantages and Challenges

AI provides enormous value for drug development mainly due to its speed and cost-efficiencies. It analyzes vast amounts of data quickly and can find drug candidates significantly faster than conventional methods, thereby decreasing time and cost in the drug development cycle. However, the amount and quality of training data significantly restricts its effectiveness, showing that AI models may be less accurate when utilizing new biological systems [93]. Although antibiotic candidates are highly predictive in models, it is crucial to experimentally validate candidate molecules and demonstrate that they retain their efficacy and safety. To fulfill the promise of computational predictions, we require microbiologists and computational scientists to work together closely so that laboratory testing can provide insights into and confirm predictions. Lastly, many models (especially deep learning) are often seen as "black boxes," making explaining how they generate predictions challenging. Higher transparency and interpretability of the models are essential for wide acceptance in antibiotic discovery [90].

10. Decreased Industry Investment into Antibacterial Drug Development

Even with all of the academic research efforts working towards improvements in antibacterial therapies, the lack of interest from the pharmaceutical industry in investing in the development of new antibacterial drugs is a quite significant hurdle in the fight against the increasing crisis of antimicrobial resistance. This has been related to a variety of factors, including financial barriers, scientific barriers, regulatory barriers, and the poor economic model of antibiotic development.

10.1. Unprofitable Antibiotics

Compared to drugs for chronic diseases, antibiotics have generally been viewed as less profitable to develop. Antibiotics are typically given over the short term, making them less suited for long-term revenue. By contrast, drugs for chronic diseases provide steady streams of income, as

patients will take the drugs for life. In addition, new antibiotics are being used as last-line treatments, effectively lowering their market potential [20]. These are economic realities that discourage pharmaceutical companies from investing in antibiotics R&D, especially when taking the risks associated with the discovery and approval of these products into account [96].

10.2. Challenges in Science and Technology

The drug discovery of low-hanging fruits has mostly been exploited, so it is becoming increasingly difficult to identify novel compounds with broad efficacy against multiple targets. Moreover, bacteria develop resistance mechanisms on a regular basis, shrinking the therapeutic window available for recently discovered antibiotics before resistance arises [97]. The complexity of bacterial resistance also makes developing effective antibiotics even more difficult. Bacteria such as *P. aeruginosa* and *A. baumannii* harbor various layers of resistance like efflux pumps, biofilm formation and enzymatic degradation of drugs. These contribute to the challenge of identifying new compounds or drug combinations that can circumvent or overcome mechanisms of resistance [98].

10.3. Obstacles in Regulation and Market

The regulatory environment for antibiotics is affecting developers more heavily. Finally, the costs and time to produce clinical trial data are significant barriers, especially concerning antibiotics. Regulatory agencies often demand that extensive clinical trials be performed to demonstrate the efficacy and safety of a drug against resistant strains, potentially involving special patient populations that are challenging to recruit. Moreover, traditional non-inferiority trial designs for antibiotic development do not always deliver conclusive evidence of efficacy against resistant pathogens, and this complicates the approval process [99]. Moreover, profitability after market introduction is also uncertain, as antibiotic stewardship programs promote judicious use of new antibiotics in order to defeat resistance, limiting potential sales. Preserving the effectiveness and urgency of antibiotics versus potential profitability for drug companies creates a pressure imbalance deterring innovation [100].

Creating financial incentives to make antibiotic R&D more attractive to pharmaceutical companies has been one of the main areas of efforts to revive the antibiotic pipeline. Various mechanisms have been proposed and implemented in some territories, including public funding early-stage research (push incentives) and market entry rewards (pull incentives). For example, US legislation such as the Generating Antibiotic Incentives Now (GAIN) Act has offered financial rewards and longer exclusivity periods for companies working on new antibiotics [19]. Yet these incentives were little more than band-aids applied to a patient with declining investment vital signs.

New antibiotics for resistant pathogens tend to be derivatives of existing compounds rather than new chemical entities, thus primarily offering incremental health benefits [101]. In addition, the lack of a long-term sustainable business model for antibiotics has deterred pharmaceutical companies from participating in these programs. Potential solutions include innovative financial models that reward companies based on the efficacy of their antibiotics to maintain low levels of resistance (e.g., “antibiotic susceptibility bonus” [100]).

Due to the crisis of global antibiotic resistance, effective international collaboration is needed to pool resources for antibiotic funding, regulation, and stewardship initiatives [102]. Initiatives like the Wellcome Trust’s Drug-Resistant Infections Priority Program aim to develop a sustainable ecosystem for antibiotic R&D, promote public-private partnerships to provide financial incentives for sustainable, long-term investment into the R&D of new antibiotics [96].

11. Conclusions

The emergence of bacterial infections and MDR organisms is driven by a combination of factors, including antibiotic abuse and misuse, HGT, environmental contamination, and hospital dynamics. To respond to this worldwide threat, action is needed to ensure the appropriate use of antibiotics, enhance infection control practices, and reduce the transmission of bacteria-carrying resistance genes in healthcare, agriculture, and the environment. New antibiotics acting against bacterial growth and survival mechanisms may provide further benefits over classical antibiotics, such as improved activity against resistant pathogens, reduced toxicity, and the potential for resistance development to be delayed. Focusing either on previously unused bacterial processes or combination therapies, these new approaches underline the hope of circumventing the global antibiotic resistance crisis. However, difficulties remain with targeting of the Gram-negative OM in bacterial pathogens, including permeability barriers to macromolecules and efflux pumps that extrude small molecules to prevent their intracellular activity or even cytotoxicity towards bacteria. Figuring out better OM assembly systems, optimizing drug design, and combining therapies are pushing the boundaries toward overcoming these barriers.

In this post-genomic era, with the structure-function-based characterization of a plethora of novel molecular targets such as histidine kinases, protein and lipid biosynthesis enzymes, quorum-sensing systems, and DNA gyrase, such targets provide avenues to generate new therapeutics that evade recognized drug resistance mechanisms and can be used against MDR organisms with broader utility.

Whole-genome and metagenomic methods are central to predicting resistance, tracking its dissemination, and discovering new antibiotic agents. The ongoing development of bioinformatics tools and third-generation sequencing platforms support such tasks. In addition, these strategies can give public health agencies the ability to respond promptly to new threats, forecast resistance, and customize interventions. They will be crucial to tackling the increasing threat of antibiotic resistance and ultimately improving health at a global level with public health frameworks that integrate these technologies.

AI is transforming antibiotic discovery by providing capabilities for novel compound identification, resistance mechanism prediction, and drug combination optimization. But it continues to face challenges, especially around data availability and model explainability.

Economics, regulatory pathways, and scientific hurdles are the main reasons why the pharmaceutical industry has receded from developing antibiotics. Antibiotic treatments consist of a few doses over short periods of time, which means they have a very slim profit margin, even when such drugs are costly to develop, which makes companies reluctant to do antibiotic R&D in the first place. Although some financial incentives, such as market entry rewards and longer exclusivity periods, were introduced in 2005 to try to spur innovation using the profit motive, these developments have signified little actual successful innovation.

There is no panacea for developing new antibacterial drugs; a multifaceted approach, including resistance-resistant strategies, reviving older drugs, targeting bacterial metabolism, and utilizing advanced technologies such as nanotechnology and systems biology, etc., will be essential to stave off this public health crisis for the foreseeable future. The new strategies bring hope in the fight against these multidrug-resistant pathogens but will need more research, funding, and interdisciplinary cooperation to succeed.

Author Contributions: GAN-V and EL-R contributed equally to the review of literature, writing, and discussion of the present manuscript. JAO-R contributed to the review of the current antibacterials section and tables. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar, GS, Authia G, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. 2022. *The Lancet* 10 (1) 112410. doi: 10.1038/s41467-019-08853-3
2. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. ISBN 978-92-4-009346-1.
3. Muñoz KA, Ulrich RJ, Vasan AK, Sinclair M, Wen PC, Holmes J, Lee HY, et al. A Gram-negative –selective antibiotic that spares the gut microbiome *Nature* 2024 630 (429-436) Epub May 29. doi: <https://doi.org/10.1038/s41586-024-07502-0>.
4. Blake KS, Choi J, Dantas G. Approaches for characterizing and tracking hospital-associated multidrug-resistant bacteria. *Cell Mol Life Sci.* 2021 Mar;78(6):2585-2606. doi: 10.1007/s00018-020-03717-2. Epub 2021 Feb 13. PMID: 33582841; PMCID: PMC8005480.
5. Kim M, Park J, Kang M, Yang J, Park W. Gain and loss of antibiotic resistant genes in multidrug resistant bacteria: One Health perspective. *J Microbiol.* 2021 Jun;59(6):535-545. doi: 10.1007/s12275-021-1085-9. Epub 2021 Apr 20. PMID: 33877574.
6. Lerminiaux NA, Cameron ADS. Horizontal transfer of antibiotic resistance genes in clinical environments. *Can J Microbiol.* 2019 Jan;65(1):34-44. doi: 10.1139/cjm-2018-0275. Epub 2018 Sep 24. PMID: 30248271.
7. Evans DR, Griffith MP, Sundermann AJ, Shutt KA, Saul MI, Mustapha MM, Marsh JW, Cooper VS, Harrison LH, Van Tyne D. Systematic detection of horizontal gene transfer across genera among multidrug-resistant bacteria in a single hospital. *Elife.* 2020 Apr 14;9:e53886. doi: 10.7554/eLife.53886. PMID: 32285801; PMCID: PMC7156236.
8. McInnes RS, McCallum GE, Lamberte LE, van Schaik W. Horizontal transfer of antibiotic resistance genes in the human gut microbiome. *Curr Opin Microbiol.* 2020 Feb;53:35-43. doi: 10.1016/j.mib.2020.02.002. Epub 2020 Mar 3. PMID: 32143027.
9. Pavlova N, Traykovska M, Penchovsky R. Targeting FMN, TPP, SAM-I, and glmS Riboswitches with Chimeric Antisense Oligonucleotides for Completely Rational Antibacterial Drug Development. *Antibiotics (Basel).* 2023 Nov 8;12(11):1607. doi: 10.3390/antibiotics12111607. PMID: 37998809; PMCID: PMC10668854.
10. Binopal G, Mabanglo MF, Goodreid JD, Leung E, Barghash MM, Wong KS, Lin F, Cossette M, Bansagi J, Song B, Balasco Serrão VH, Pai EF, Batey RA, Gray-Owen SD, Houry WA. Development of Antibiotics That Dysregulate the Neisserial ClpP Protease. *ACS Infect Dis.* 2020 Dec 11;6(12):3224-3236. doi: 10.1021/acsinfecdis.0c00599. Epub 2020 Nov 25. PMID: 33237740; PMCID: PMC8388192.
11. Talat A, Bashir Y, Khan AU. Repurposing of antibiotics: sense or non-sense. *Front. Pharmacol.* 2022. Epub 2022 Feb 21 13(833005). doi: 10.3389/fphar.2022.833005
12. Rezzoagli C, Archetti M, Mignot I, Baumgartner M, Kümmerli R. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in *Pseudomonas aeruginosa*. *PLoS Biol.* 2020 Aug 18;18(8):e3000805. doi: 10.1371/journal.pbio.3000805. PMID: 32810152; PMCID: PMC7433856.
13. Provenzani A, Hospodar AR, Meyer AL, Leonardi Vinci D, Hwang EY, Butrus CM, Polidori P. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. *Int J Clin Pharm.* 2020 Aug;42(4):1016-1025. doi: 10.1007/s11096-020-01089-y. Epub 2020 Jul 7. PMID: 32638294.

14. Hart EM, Mitchell AM, Konovalova A, Grabowicz M, Sheng J, Han X, Rodriguez-Rivera FP, Schwaid AG, Malinverni JC, Balibar CJ, Bodea S, Si Q, Wang H, Homsher MF, Painter RE, Ogawa AK, Sutterlin H, Roemer T, Black TA, Rothman DM, Walker SS, Silhavy TJ. A small-molecule inhibitor of BamA impervious to efflux and the outer membrane permeability barrier. *Proc Natl Acad Sci U S A*. 2019 Oct 22;116(43):21748-21757. doi: 10.1073/pnas.1912345116. Epub 2019 Oct 7. PMID: 31591200; PMCID: PMC6815139.
15. Zhao S, Adamiak JW, Bonifay V, Mehla J, Zgurskaya HI, Tan DS. Defining new chemical space for drug penetration into Gram-negative bacteria. *Nat Chem Biol*. 2020 Dec;16(12):1293-1302. doi: 10.1038/s41589-020-00674-6. Epub 2020 Nov 16. PMID: 33199906; PMCID: PMC7897441.
16. Durand-Reville TF, Miller AA, O'Donnell JP, Wu X, Sylvester MA, Guler S, Iyer R, Shapiro AB, Carter NM, Velez-Vega C, Moussa SH, McLeod SM, Chen A, Tanudra AM, Zhang J, Comita-Prevoir J, Romero JA, Huynh H, Ferguson AD, Horanyi PS, Mayclin SJ, Heine HS, Drusano GL, Cummings JE, Slayden RA, Tommasi RA. Rational design of a new antibiotic class for drug-resistant infections. *Nature*. 2021 Sep;597(7878):698-702. doi: 10.1038/s41586-021-03899-0. Epub 2021 Sep 15. PMID: 34526714.
17. Zhu JW, Zhang SJ, Wang WG, Jiang H. Strategies for Discovering New Antibiotics from Bacteria in the Post-Genomic Era. *Curr Microbiol*. 2020 Nov;77(11):3213-3223. doi: 10.1007/s00284-020-02197-8. Epub 2020 Sep 14. PMID: 32929578.
18. Alkatheri AH, Yap PSX, Abushelaibi A, Lai KS, Cheng WH, Lim SHE. Microbial genomics: Innovative targets and mechanisms. *Antibiotics* 2023, 12(2), 190. <https://doi.org/10.3390/antibiotics12020190> Epub 2023 Jan 17
19. Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW; Infectious Diseases Society of America. The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility? *Clin Infect Dis*. 2019 Jun 18;69(1):1-11. doi: 10.1093/cid/ciz089. PMID: 30715222.
20. Böttcher, L., Gersbach, H. A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development. *Bull Math Biol* 84, 59 (2022). <https://doi.org/10.1007/s11538-022-01013-7>
21. Ding M, Ye Z, Liu L, Wang W, Chen Q, Zhang F, Wang Y, Sjöling Å, Martín-Rodríguez AJ, Hu R, Chen W, Zhou Y. Subinhibitory antibiotic concentrations promote the horizontal transfer of plasmid-borne resistance genes from *Klebsiella pneumoniae* to *Escherichia coli*. *Front Microbiol*. 2022 Nov 7;13:1017092. doi: 10.3389/fmicb.2022.1017092. PMID: 36419429; PMCID: PMC9678054.
22. Kunhikannan S, Thomas CJ, Franks AE, Mahadevaiah S, Kumar S, Petrovski S. Environmental hotspots for antibiotic resistance genes. *Microbiologyopen*. 2021 Jun;10(3):e1197. doi: 10.1002/mbo3.1197. PMID: 34180594; PMCID: PMC8123917.
23. Jian Z, Zeng L, Xu T, Sun S, Yan S, Yang L, Huang Y, Jia J, Dou T. Antibiotic resistance genes in bacteria: Occurrence, spread, and control. *J Basic Microbiol*. 2021 Dec;61(12):1049-1070. doi: 10.1002/jobm.202100201. Epub 2021 Oct 14. PMID: 34651331.
24. Lu J, Wang Y, Jin M, Yuan Z, Bond P, Guo J. Both silver ions and silver nanoparticles facilitate the horizontal transfer of plasmid-mediated antibiotic resistance genes. *Water Res*. 2020 Feb 1;169:115229. doi: 10.1016/j.watres.2019.115229. Epub 2019 Oct 25. PMID: 31783256.
25. Alav, Ilyas and Buckner, Michelle M. C. 2023. Non-antibiotic compounds associated with humans and the environment can promote horizontal transfer of antimicrobial resistance genes, *Critical Reviews in Microbiology*, DOI: 10.1080/1040841X.2023.2233603
26. Engin AB, Engin A. Nanoantibiotics: A Novel Rational Approach to Antibiotic Resistant Infections. *Curr Drug Metab*. 2019;20(9):720-741. doi: 10.2174/1389200220666190806142835. PMID: 31385767.

27. Kim J, Greenberg DE, Pifer R, Jiang S, Xiao G, Shelburne SA, Koh A, Xie Y, Zhan X. VAMPr: VArIant Mapping and Prediction of antibiotic resistance via explainable features and machine learning. *PLoS Comput Biol.* 2020 Jan 13;16(1):e1007511. doi: 10.1371/journal.pcbi.1007511. PMID: 31929521; PMCID: PMC7015433.
28. Di YP, Lin Q, Chen C, Montelaro RC, Doi Y, Deslouches B. Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. *Sci Adv.* 2020 May 1;6(18):eaay6817. doi: 10.1126/sciadv.aay6817. PMID: 32426473; PMCID: PMC7195177.
29. Lehman KM, Grabowicz M. Countering Gram-Negative Antibiotic Resistance: Recent Progress in Disrupting the Outer Membrane with Novel Therapeutics. *Antibiotics (Basel).* 2019 Sep 24;8(4):163. doi: 10.3390/antibiotics8040163. PMID: 31554212; PMCID: PMC6963605.
30. Vasan AK, Haloi N, Ulrich RJ, Metcalf ME, Wen PC, Metcalf WW, Hergenrother PJ, Shukla D, Tajkhorshid E. Role of internal loop dynamics in antibiotic permeability of outer membrane porins. *Proc Natl Acad Sci U S A.* 2022 Feb 22;119(8):e2117009119. doi: 10.1073/pnas.2117009119. PMID: 35193963; PMCID: PMC8872756.
31. Choi U, Lee CR. Antimicrobial Agents That Inhibit the Outer Membrane Assembly Machines of Gram-Negative Bacteria. *J Microbiol Biotechnol.* 2019 Jan 28;29(1):1-10. doi: 10.4014/jmb.1804.03051. PMID: 29996592.
32. Kaur H, Jakob RP, Marzinek JK, Green R, Imai Y, Bolla JR, Agustoni E, Robinson CV, Bond PJ, Lewis K, Maier T, Hiller S. The antibiotic darobactin mimics a β -strand to inhibit outer membrane insertase. *Nature.* 2021 May;593(7857):125-129. doi: 10.1038/s41586-021-03455-w. Epub 2021 Apr 14. PMID: 33854236.
33. Kany AM, Fries F, Seyfert CE, Porten C, Deckarm S, Chacón Ortiz M, Dubarry N, Vaddi S, Große M, Bernecker S, Sandargo B, Müller AV, Bacqué E, Stadler M, Herrmann J, Müller R. In Vivo Activity Profiling of Biosynthetic Darobactin D22 against Critical Gram-Negative Pathogens. *ACS Infect Dis.* 2024 Dec 13;10(12):4337-4346. doi: 10.1021/acsinfecdis.4c00687. Epub 2024 Nov 20. PMID: 39565008; PMCID: PMC11650638.
34. Klobucar K, Côté JP, French S, Borrillo L, Guo ABY, Serrano-Wu MH, Lee KK, Hubbard B, Johnson JW, Gaulin JL, Magolan J, Hung DT, Brown ED. Chemical Screen for Vancomycin Antagonism Uncovers Probes of the Gram-Negative Outer Membrane. *ACS Chem Biol.* 2021 May 21;16(5):929-942. doi: 10.1021/acscchembio.1c00179. Epub 2021 May 11. PMID: 33974796.
35. MacNair CR, Brown ED. Outer membrane disruption overcomes intrinsic, acquired, and spontaneous antibiotic resistance. *mBio* 2020 Sep 22; 11(5) :e01615-20. Doi: 10.1128/mBio.01615-20
36. French S, Farha M, Ellis MJ, Sameer Z, Côté JP, Cotroneo N, Lister T, Rubio A, Brown ED. Potentiation of Antibiotics against Gram-Negative Bacteria by Polymyxin B Analogue SPR741 from Unique Perturbation of the Outer Membrane. *ACS Infect Dis.* 2020 Jun 12;6(6):1405-1412. doi: 10.1021/acsinfecdis.9b00159. Epub 2019 Oct 23. PMID: 31566948.
37. Romano KP, Hung DT. Targeting LPS biosynthesis and transport in gram-negative bacteria in the era of multi-drug resistance. *Biochim Biophys Acta Mol Cell Res.* 2023 Mar;1870(3):119407. doi: 10.1016/j.bbamcr.2022.119407. Epub 2022 Dec 18. PMID: 36543281; PMCID: PMC9922520
38. Sharma S, Zhou R, Wan L, Feng S, Song K, Xu C, Li Y, Liao M. Mechanism of LolCDE as a molecular extruder of bacterial triacylated lipoproteins. *Nat Commun.* 2021 Aug 3;12(1):4687. doi: 10.1038/s41467-021-24965-1. PMID: 34344901; PMCID: PMC8333309.
39. Grabowicz M, Silhavy TJ. Redefining the essential trafficking pathway for outer membrane lipoproteins. *Proc Nat Acad Sci USA* 2017 May 2; 114 (18): 4769-4774. Doi: 10.1073/pnas.1702248114 Epub 2017 Apr 17
40. Grabowicz M. Lipoproteins and Their Trafficking to the Outer Membrane. *EcoSal Plus.* 2019 Mar;8(2). doi: 10.1128/ecosalplus.ESP-0038-2018. PMID: 30900542.

41. Diao J, Komura R, Sano T, Pantua H, Storek KM, Inaba H, Ogawa H, Noland CL, Peng Y, Gloor SL, Yan D, Kang J, Katakam AK, Volny M, Liu P, Nickerson NN, Sandoval W, Austin CD, Murray J, Rutherford ST, Reichelt M, Xu Y, Xu M, Yanagida H, Nishikawa J, Reid PC, Cunningham CN, Kapadia SB. Inhibition of *Escherichia coli* Lipoprotein Diacylglyceryl Transferase Is Insensitive to Resistance Caused by Deletion of Braun's Lipoprotein. *J Bacteriol.* 2021 Jun 8;203(13):e0014921. doi: 10.1128/JB.00149-21. Epub 2021 Jun 8. PMID: 33875545; PMCID: PMC8316002.
42. May KL, Lehman KM, Mitchell AM, Grabowicz M. A Stress Response Monitoring Lipoprotein Trafficking to the Outer Membrane. *mBio.* 2019 May 28;10(3):e00618-19. doi: 10.1128/mBio.00618-19. PMID: 31138744; PMCID: PMC6538781.
43. Yu B, Roy Choudhury M, Yang X, Benoit SL, Womack E, Van Mouwerik Lyles K, Acharya A, Kumar A, Yang C, Pavlova A, Zhu M, Yuan Z, Gumbart JC, Boykin DW, Maier RJ, Eichenbaum Z, Wang B. Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants. *ACS Infect Dis.* 2022 Aug 12;8(8):1491-1508. doi: 10.1021/acsinfectdis.2c00121. Epub 2022 Jul 8. PMID: 35801980; PMCID: PMC11227883.
44. Liu Y, Li R, Xiao X, Wang Z. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria. *Crit Rev Microbiol.* 2019 May;45(3):301-314. doi: 10.1080/1040841X.2019.1599813. Epub 2019 Apr 15. PMID: 30985240.
45. Snyderman DR, McDermott LA, Jacobus NV, Kerstein K, Grossman TH, Sutcliffe JA. Evaluation of the *In Vitro* Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates. *Antimicrob Agents Chemother.* 2018 Apr 26;62(5):e02206-17. doi: 10.1128/AAC.02206-17. PMID: 29483114; PMCID: PMC5923129.
46. Liao X, Liang Q, Dai X, Wu S, Duan C, Luo Z, Xie X. *In vitro* activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China. *Front Microbiol.* 2024 Nov 18;15:1504013. doi: 10.3389/fmicb.2024.1504013. PMID: 39624714; PMCID: PMC11609169.
47. Sato T, Yamawaki K. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin. *Clin Infect Dis.* 2019 Nov 13;69(Suppl 7):S538-S543. doi: 10.1093/cid/ciz826. PMID: 31724047; PMCID: PMC6853759.
48. Karakostas S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia*: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2024 Feb;30(2):178-188. doi: 10.1016/j.cmi.2023.08.029. Epub 2023 Sep 4. PMID: 37666449.
49. Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant *Klebsiella pneumoniae* isolates. *Antimicrob Agents Chemother.* 2009 Oct;53(10):4504-7. doi: 10.1128/AAC.00556-09. PMID: 19770287; PMCID: PMC2764147.
50. Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against β -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). *J Antimicrob Chemother.* 2017 Oct 1;72(10):2792-2795. doi: 10.1093/jac/dkx261. PMID: 29091224.
51. Yan K, Liang B, Zhang G, Wang J, Zhu M, Cai Y. Efficacy and Safety of Plazomicin in the Treatment of Enterobacterales Infections: A Meta-analysis of Randomized Controlled Trials. *Open Forum Infect Dis.* 2022 Aug 29;9(9):ofac429. doi: 10.1093/ofid/ofac429. PMID: 36092826; PMCID: PMC9454024.
52. Tulkens PM, Van Bambeke F, Zinner SH. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. *Clin Infect Dis.* 2019 Apr 8;68(Suppl 3):S213-S222. doi: 10.1093/cid/ciy1079. PMID: 30957164; PMCID: PMC6452001.

53. Ribeiro ÁCDS, Santos FF, Valiatti TB, Lenzi MH, Santos INM, Neves RFB, Moses IB, Meneses JP, Di Sessa RGG, Salles MJ, Gales AC. Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis. *Braz J Infect Dis*. 2024 Nov-Dec;28(6):103867. doi: 10.1016/j.bjid.2024.103867. Epub 2024 Sep 18. PMID: 39305936; PMCID: PMC11490911.
54. Culp EJ, Waglechner N, Wang W, Fiebig-Comyn AA, Hsu YP, Koteva K, Sychantha D, Coombes BK, Van Nieuwenhze MS, Brun YV, Wright GD. Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling. *Nature*. 2020 Feb;578(7796):582-587. doi: 10.1038/s41586-020-1990-9. Epub 2020 Feb 12. PMID: 32051588.
55. Yao J, Zou P, Cui Y, Quan L, Gao C, Li Z, Gong W, Yang M. Recent Advances in Strategies to Combat Bacterial Drug Resistance: Antimicrobial Materials and Drug Delivery Systems. *Pharmaceutics*. 2023 Apr 7;15(4):1188. doi: 10.3390/pharmaceutics15041188. PMID: 37111673; PMCID: PMC10141387.
56. Ye J, Chen X. Current Promising Strategies against Antibiotic-Resistant Bacterial Infections. *Antibiotics (Basel)*. 2022 Dec 30;12(1):67. doi: 10.3390/antibiotics12010067. PMID: 36671268; PMCID: PMC9854991.
57. Fihn CA, Carlson EE. Targeting a highly conserved domain in bacterial histidine kinases to generate inhibitors with broad spectrum activity. *Curr Opin Microbiol*. 2021 Jun;61:107-114. doi: 10.1016/j.mib.2021.03.007. Epub 2021 Apr 28. PMID: 33932730; PMCID: PMC8189720.
58. Chen H, Yu C, Wu H, Li G, Li C, Wu H, Hong W, Yang X, You X. Recent Advances in histidine kinase-targeted antimicrobial agents. *Front Chem* 2022 Jul 4;10:866392. doi: 10.3389/fchem.2022.866392. eCollection 2022
59. Mori M, Sammartino JC, Costantino L, Gelain A, Meneghetti F, Villa S, Chiarelli LR. An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from *Mycobacterium tuberculosis*. *Curr Top Med Chem*. 2019;19(9):646-661. doi: 10.2174/1568026619666190227182701. PMID: 30827246.
60. Zhao X, Yu Z, Ding T. Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria. *Microorganisms*. 2020 Mar 17;8(3):425. doi: 10.3390/microorganisms8030425. PMID: 32192182; PMCID: PMC7143945.
61. Fernandes PB, Reed P, Monteiro JM, Pinho MG. Revisiting the Role of VraTSR in *Staphylococcus aureus* Response to Cell Wall-Targeting Antibiotics. *J Bacteriol*. 2022 Aug 16;204(8):e0016222. doi: 10.1128/jb.00162-22. Epub 2022 Jul 13. PMID: 35862765; PMCID: PMC9380581.
62. Zhao J, Cochrane CS, Najeeb J, Gooden D, Sciandra C, Fan P, Lemaitre N, Newns K, Nicholas RA, Guan Z, Thaden JT, Fowler VG Jr, Spasojevic I, Sebbane F, Toone EJ, Duncan C, Gammans R, Zhou P. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens. *Sci Transl Med*. 2023 Aug 9;15(708):eadf5668. doi: 10.1126/scitranslmed.adf5668. Epub 2023 Aug 9. PMID: 37556556; PMCID: PMC10785772.
63. Zhou P, Hong J. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria. *Acc Chem Res*. 2021 Apr 6;54(7):1623-1634. doi: 10.1021/acs.accounts.0c00880. Epub 2021 Mar 15. PMID: 33720682; PMCID: PMC9593327.
64. Fan S, Li D, Yan M, Feng X, Lv G, Wu G, Jin Y, Wang Y, Yang Z. The Complex Structure of Protein AaLpxC from *Aquifex aeolicus* with ACHN-975 Molecule Suggests an Inhibitory Mechanism at Atomic-Level against Gram-Negative Bacteria. *Molecules*. 2021 Mar 7;26(5):1451. doi: 10.3390/molecules26051451. PMID: 33800069; PMCID: PMC7962117.

65. Li Q, Cebrián R, Montalbán-López M, Ren H, Wu W, Kuipers OP. Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens. *Commun Biol*. 2021 Jan 4;4(1):31. doi: 10.1038/s42003-020-01511-1. PMID: 33398076; PMCID: PMC7782785.
66. Dewangan RP, Verma DP, Verma NK, Gupta A, Pant G, Mitra K, Habib S, Ghosh JK. Spermine-Conjugated Short Proline-Rich Lipopeptides as Broad-Spectrum Intracellular Targeting Antibacterial Agents. *J Med Chem*. 2022 Apr 14;65(7):5433-5448. doi: 10.1021/acs.jmedchem.1c01809. Epub 2022 Mar 17. PMID: 35297625.
67. Ibrahim TS, Almalki AJ, Moustafa AH, Allam RM, Abuo-Rahma GEA, El Subbagh HI, Mohamed MFA. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study. *Bioorg Chem*. 2021 Jun;111:104885. doi: 10.1016/j.bioorg.2021.104885. Epub 2021 Apr 1. PMID: 33838559.
68. Van Camp PJ, Haslam DB, Porollo A. Prediction of Antimicrobial Resistance in Gram-Negative Bacteria From Whole-Genome Sequencing Data. *Front Microbiol*. 2020 May 25;11:1013. doi: 10.3389/fmicb.2020.01013. PMID: 32528441; PMCID: PMC7262952.
69. Christofferson AJ, Elbourne A, Cheeseman S, Shi Y, Rolland M, Cozzolino D, Chapman J, McConville CF, Crawford RJ, Wang PY, Truong NP, Anastasaki A, Truong VK. Conformationally tuned antibacterial oligomers target the peptidoglycan of Gram-positive bacteria. *J Colloid Interface Sci*. 2020 Nov 15;580:850-862. doi: 10.1016/j.jcis.2020.07.090. Epub 2020 Jul 20. PMID: 32736272.
70. Hua X, Liang Q, Deng M, He J, Wang M, Hong W, Wu J, Lu B, Leptihn S, Yu Y, Chen H. BacAnt: A Combination Annotation Server for Bacterial DNA Sequences to Identify Antibiotic Resistance Genes, Integrons, and Transposable Elements. *Front Microbiol*. 2021 Jul 23;12:649969. doi: 10.3389/fmicb.2021.649969. PMID: 34367079; PMCID: PMC8343408.
71. Skinnider MA, Johnston CW, Gunabalasingam M, Merwin NJ, Kieliszek AM, MacLellan RJ, Li H, Ranieri MRM, Webster ALH, Cao MPT, Pfeifle A, Spencer N, To QH, Wallace DP, Dejong CA, Magarvey NA. Comprehensive prediction of secondary metabolite structure and biological activity from microbial genome sequences. *Nat Commun*. 2020 Nov 27;11(1):6058. doi: 10.1038/s41467-020-19986-1. PMID: 33247171; PMCID: PMC7699628.
72. Asante J, Osei Sekyere J. Understanding antimicrobial discovery and resistance from a metagenomic and metatranscriptomic perspective: advances and applications. *Environ Microbiol Rep*. 2019 Apr;11(2):62-86. doi: 10.1111/1758-2229.12735. Epub 2019 Feb 14. PMID: 30637962.
73. Sukhum KV, Diorio-Toth L, Dantas G. Genomic and Metagenomic Approaches for Predictive Surveillance of Emerging Pathogens and Antibiotic Resistance. *Clin Pharmacol Ther*. 2019 Sep;106(3):512-524. doi: 10.1002/cpt.1535. Epub 2019 Jul 22. PMID: 31172511; PMCID: PMC6692204.
74. La, TM., Kim, Jh., Kim, T. et al. The optimal standard protocols for whole-genome sequencing of antibiotic-resistant pathogenic bacteria using third-generation sequencing platforms. *Mol. Cell. Toxicol*. 17, 493–501 (2021). <https://doi.org/10.1007/s13273-021-00157-2>
75. Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo TH, Oliver A, Cabot G, Kola A, Gastmeier P, Hogardt M, Jonas D, Mofrad MR, Bremges A, McHardy AC, Häussler S. Predicting antimicrobial resistance in *Pseudomonas aeruginosa* with machine learning-enabled molecular diagnostics. *EMBO Mol Med*. 2020 Mar 6;12(3):e10264. doi: 10.15252/emmm.201910264. Epub 2020 Feb 12. PMID: 32048461; PMCID: PMC7059009.
76. Hendriksen RS, Bortolaia V, Tate H, Tyson GH, Aarestrup FM, McDermott PF. Using Genomics to Track Global Antimicrobial Resistance. *Front Public Health*. 2019 Sep 4;7:242. doi: 10.3389/fpubh.2019.00242. PMID: 31552211; PMCID: PMC6737581.

77. Peter S, Bosio M, Gross C, Bezdan D, Gutierrez J, Oberhettinger P, Liese J, Vogel W, Dörfel D, Berger L, Marschal M, Willmann M, Gut I, Gut M, Autenrieth I, Ossowski S. Tracking of Antibiotic Resistance Transfer and Rapid Plasmid Evolution in a Hospital Setting by Nanopore Sequencing. *mSphere*. 2020 Aug 19;5(4):e00525-20. doi: 10.1128/mSphere.00525-20. PMID: 32817379; PMCID: PMC7440845.
78. Pillay S, Calderón-Franco D, Urhan A, Abeel T. Metagenomic-based surveillance systems for antibiotic resistance in non-clinical settings. *Front Microbiol*. 2022 Dec 2;13:1066995. doi: 10.3389/fmicb.2022.1066995. PMID: 36532424; PMCID: PMC9755710.
79. Hicks AL, Kissler SM, Mortimer TD, Ma KC, Taiaroa G, Ashcroft M, Williamson DA, Lipsitch M, Grad YH. Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants. *Elife*. 2020 Jun 30;9:e56367. doi: 10.7554/eLife.56367. PMID: 32602459; PMCID: PMC7326491.
80. Tyson GH, Ceric O, Guag J, Nemser S, Borenstein S, Slavic D, Lippert S, McDowell R, Krishnamurthy A, Korosec S, Friday C, Pople N, Saab ME, Fairbrother JH, Janelle I, McMillan D, Bommineni YR, Simon D, Mohan S, Sanchez S, Phillips A, Bartlett P, Naikare H, Watson C, Sahin O, Stinman C, Wang L, Maddox C, DeShambo V, Hendrix K, Lubelski D, Burklund A, Lubbers B, Reed D, Jenkins T, Erol E, Patel M, Locke S, Fortner J, Peak L, Balasuriya U, Mani R, Kettler N, Olsen K, Zhang S, Shen Z, Landinez MP, Thornton JK, Thachil A, Byrd M, Jacob M, Krogh D, Webb B, Schaan L, Patil A, Dasgupta S, Mann S, Goodman LB, Franklin-Guild RJ, Anderson RR, Mitchell PK, Cronk BD, Aprea M, Cui J, Jurkovic D, Prarat M, Zhang Y, Shiplett K, Campos DD, Rubio JVB, Ramachandran A, Talent S, Tewari D, Thirumalapura N, Kelly D, Barnhart D, Hall L, Rankin S, Dietrich J, Cole S, Scaria J, Antony L, Lawhon SD, Wu J, McCoy C, Dietz K, Wolking R, Alexander T, Burbick C, Reimschuessel R. Genomics accurately predicts antimicrobial resistance in *Staphylococcus pseudintermedius* collected as part of Vet-LIRN resistance monitoring. *Vet Microbiol*. 2021 Mar;254:109006. doi: 10.1016/j.vetmic.2021.109006. Epub 2021 Feb 4. PMID: 33581494.
81. Stracy M, Snitser O, Yelin I, Amer Y, Parizade M, Katz R, Rimler G, Wolf T, Herzel E, Koren G, Kuint J, Foxman B, Chodick G, Shalev V, Kishony R. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. *Science*. 2022 Feb 25;375(6583):889-894. doi: 10.1126/science.abg9868. Epub 2022 Feb 24. PMID: 35201862; PMCID: PMC7612469.
82. Ceric O, Tyson GH, Goodman LB, Mitchell PK, Zhang Y, Prarat M, Cui J, Peak L, Scaria J, Antony L, Thomas M, Nemser SM, Anderson R, Thachil AJ, Franklin-Guild RJ, Slavic D, Bommineni YR, Mohan S, Sanchez S, Wilkes R, Sahin O, Hendrix GK, Lubbers B, Reed D, Jenkins T, Roy A, Paulsen D, Mani R, Olsen K, Pace L, Pulido M, Jacob M, Webb BT, Dasgupta S, Patil A, Ramachandran A, Tewari D, Thirumalapura N, Kelly DJ, Rankin SC, Lawhon SD, Wu J, Burbick CR, Reimschuessel R. Enhancing the one health initiative by using whole genome sequencing to monitor antimicrobial resistance of animal pathogens: Vet-LIRN collaborative project with veterinary diagnostic laboratories in United States and Canada. *BMC Vet Res*. 2019 May 6;15(1):130. doi: 10.1186/s12917-019-1864-2. PMID: 31060608; PMCID: PMC6501310.
83. Hamet P, Tremblay J. Artificial intelligence in medicine. *Metabolism*. 2017 Apr 69S:S36-S40. Doi: 10.1016/j.metabol.2017.01.011. Epub 2017 Jan 11
84. Talat A, Khan AU. Artificial intelligence as a smart approach to develop antimicrobial drug molecules: A paradigm to combat drug-resistant infections. *Drug Discovery Today* 28(10325):103491, January 2023. DOI:10.1016/j.drudis.2023.103491
85. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta, RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Mol Divers* . 2021 Aug;25(3):1315-1360. doi: 10.1007/s11030-021-10217-3. Epub 2021 Apr 12.

86. Parvatikar PP, Patil S, Khaparkhantikar K, Patil S, Singh PK, Singh PK, Sahana Raghavendra V, Kulkarni RV, Raghu AV. Artificial intelligence: Machine learning approach for screening large database and drug discovery. *Antiviral Res*. 2023 Dec;220:105740. doi: 10.1016/j.antiviral.2023.105740. Epub 2023 Nov 5.
87. Stokes JM, Yang J, Swanson K, Jin W, Cubillos-Ruiz A et al. A deep learning approach to antibiotic discovery. *Cell* 181(2):475-483. DOI:10.1016/j.cell.2020.04.001
88. Lluca T, Stokes JM. Antibiotic discovery in the artificial intelligence era. *Ann N Y Acad Sci*. 2023 Jan;1519(1):74-93. doi: 10.1111/nyas.14930. Epub 2022 Nov 29. PMID: 36447334.
89. Cesaro A, Bagheri M, Torres M, Wan F, de la Fuente-Nunez C. Deep learning tools to accelerate antibiotic discovery. *Expert Opin Drug Discov*. 2023 Jul-Dec;18(11):1245-1257. doi: 10.1080/17460441.2023.2250721. Epub 2023 Oct 18. PMID: 37794737; PMCID: PMC10790350.
90. Ruiz Puentes P, Henao MC, Cifuentes J, Muñoz-Camargo C, Reyes LH, Cruz JC, Arbeláez P. Rational Discovery of Antimicrobial Peptides by Means of Artificial Intelligence. *Membranes (Basel)*. 2022 Jul 14;12(7):708. doi: 10.3390/membranes12070708. PMID: 35877911; PMCID: PMC9320227.
91. Santos-Júnior, C.D. M.D.T. Torres, Y. Duan, Á. Rodríguez del Río, T.S.B. Schmidt, H. Chong, A. Fullam, M. Kuhn, C. Zhu, A. Houseman, et al. Discovery of antimicrobial peptides in the global microbiome with machine learning *Cell*, 187 (2024), pp. 3761-3778.e16, 10.1016/j.cell.2024.05.013
92. Shi J, Yan Y, Links MG, Li L, Dillon JR, Horsch M, Kusalik A. Antimicrobial resistance genetic factor identification from whole-genome sequence data using deep feature selection. *BMC Bioinformatics*. 2019 Dec 24;20(Suppl 15):535. doi: 10.1186/s12859-019-3054-4. PMID: 31874612; PMCID: PMC6929425.
93. Melo MCR, Maasch JRMA, de la Fuente-Nunez C. Accelerating antibiotic discovery through artificial intelligence. *Commun Biol*. 2021 Sep 9;4(1):1050. doi: 10.1038/s42003-021-02586-0. PMID: 34504303; PMCID: PMC8429579.
94. Madani, B.M. 2023. The Application of Artificial Intelligence in Antibiotic Discovery: An Overview of Current and Future Perspective. *Int. J. Adv. Res.* 11(04), 1326-1332
95. Anahtar MN, Yang JH, Kanjilal S. 2021. Applications of machine learning to the problem of antimicrobial resistance: an emerging model for translational research. *J Clin Microbiol* 59:e01260-20. <https://doi.org/10.1128/JCM.01260-20>.
96. Wiecek J, Buckland-Merrett G. A View from the Wellcome Trust Drug-Resistant Infections Priority Programme: Creating a Sustainable Research and Development Ecosystem to Meet the Global Need for Antibiotics. *ACS Infect Dis*. 2020 Jun 12;6(6):1305-1307. doi: 10.1021/acsinfecdis.0c00094. PMID: 32527095.
97. Bergkessel M, Forte B, Gilbert IH. Small-Molecule Antibiotic Drug Development: Need and Challenges. *ACS Infect Dis*. 2023 Nov 10;9(11):2062-2071. doi: 10.1021/acsinfecdis.3c00189. Epub 2023 Oct 11. PMID: 37819866; PMCID: PMC10644355.
98. Church, N.A., McKillip, J.L. Antibiotic resistance crisis: challenges and imperatives. *Biologia* 76, 1535–1550 (2021). <https://doi.org/10.1007/s11756-021-00697-x>
99. Lanini S, Ioannidis JPA, Vairo F, Pletschette M, Portella G, Di Bari V, Mammone A, Pisapia R, Merler S, Nguhuni B, Langer M, Di Caro A, Edwards SJL, Petrosillo N, Zumla A, Ippolito G. Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. *Lancet Infect Dis*. 2019 Dec;19(12):e444-e451. doi: 10.1016/S1473-3099(19)30284-1. Epub 2019 Aug 23. PMID: 31451421.
100. Morel CM, Lindahl O, Harbarth S, de Kraker MEA, Edwards S, Hollis A. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. *J Antibiot (Tokyo)*. 2020 Jul;73(7):421-428. doi: 10.1038/s41429-020-0300-y. Epub 2020 Mar 19. PMID: 32203126; PMCID: PMC7292800.

101. Walesch S, Birkelbach J, Jézéquel G, Haeckl FPJ, Hegemann JD, Hesterkamp T, Hirsch AKH, Hammann P, Müller R. Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials. *EMBO Rep.* 2023 Jan 9;24(1):e56033. doi: 10.15252/embr.202256033. Epub 2022 Dec 19. PMID: 36533629; PMCID: PMC9827564.
102. Dutescu IA, Hillier SA. Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study. *Infect Drug Resist.* 2021 Feb 5;14:415-434. doi: 10.2147/IDR.S287792. PMID: 33574682; PMCID: PMC7872909.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.